Health
Jun 17, 2026
London Startup to Trial Drug Preventing Cancer Therapy Side-Effect
A London-based startup, Poolbeg Pharma, is trialing a drug to prevent cytokine release syndrome (CR…
The Breakthrough in Cancer Immunotherapy
A London-based startup, Poolbeg Pharma, is set to trial a drug at six NHS hospitals that could prevent a life-threatening side-effect of cancer immunotherapy. The oral drug, POLB 001, aims to stop cytokine release syndrome (CRS), a condition where the immune system attacks the body, leading to organ damage.
Understanding Cytokine Release Syndrome
Cytokine release syndrome occurs when the immune system overreacts to cancer immunotherapy, causing fever, increased heart rate, and potentially requiring intensive care. About 70% of people receiving cancer immunotherapies develop CRS, and there is currently no approved therapy for its prevention.
The Trial and Its Potential Impact
The drug will be tested on 30 people treated with Johnson & Johnson's blood cancer medication teclistamab at six hospitals in Britain. If successful, POLB 001 could make treatment safer and reduce costs for the NHS by allowing patients to be treated in community hospitals rather than centralized specialist cancer centers.
The Market Potential
Poolbeg estimates that around half a million people diagnosed with blood cancers will receive immunotherapy by 2031 in the US and major European countries. With a potential price of $20,000 per treatment, the market for POLB 001 could be worth $10bn.
The Future of Cancer Treatment
The trial, led by the University of Manchester and the Christie NHS Foundation Trust, is expected to yield interim data by the end of the summer. If successful, POLB 001 could become a crucial tool in the treatment of blood cancers, enabling more patients to receive life-saving immunotherapies while minimizing the risk of CRS.
#Poolbeg Pharma
#Cancer Immunotherapy
#NHS
Read More